Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer

ANNE M. AHTIKOSKI, JUHA KANGAS, RIIKKA SALONEN, ULLA PUISTOLA and PEETER KARIHTALA
Anticancer Research February 2019, 39 (2) 585-590; DOI: https://doi.org/10.21873/anticanres.13151
ANNE M. AHTIKOSKI
1Cancer and Translational Medicine Research Unit, Department of Pathology, Oulu University Hospital, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anne.ahtikoski{at}oulu.fi
JUHA KANGAS
2Department of Gynecology and Obstetrics, Pedego Research Unit, Oulu University Hospital, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RIIKKA SALONEN
1Cancer and Translational Medicine Research Unit, Department of Pathology, Oulu University Hospital, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULLA PUISTOLA
2Department of Gynecology and Obstetrics, Pedego Research Unit, Oulu University Hospital, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PEETER KARIHTALA
3Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 39 no. 2 585-590
DOI 
https://doi.org/10.21873/anticanres.13151
PubMed 
30711933

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received January 8, 2019
  • Revision received January 16, 2019
  • Accepted January 18, 2019
  • Published online February 2, 2019.

Copyright & Usage 
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. ANNE M. AHTIKOSKI1⇑,
  2. JUHA KANGAS2,
  3. RIIKKA SALONEN1,
  4. ULLA PUISTOLA2 and
  5. PEETER KARIHTALA3
  1. 1Cancer and Translational Medicine Research Unit, Department of Pathology, Oulu University Hospital, University of Oulu, Oulu, Finland
  2. 2Department of Gynecology and Obstetrics, Pedego Research Unit, Oulu University Hospital, University of Oulu, Oulu, Finland
  3. 3Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
  1. Correspondence to: Anne Ahtikoski, MD, Ph.D., Department of Pathology, P.O. Box 50, 90029 Oulu University Hospital, Finland. Tel: +358 401347325, Fax: +358 83152177, e-mail: anne.ahtikoski{at}oulu.fi
View Full Text

Statistics from Altmetric.com

Cited By...

  • 12 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 39, Issue 2
February 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer
ANNE M. AHTIKOSKI, JUHA KANGAS, RIIKKA SALONEN, ULLA PUISTOLA, PEETER KARIHTALA
Anticancer Research Feb 2019, 39 (2) 585-590; DOI: 10.21873/anticanres.13151

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer
ANNE M. AHTIKOSKI, JUHA KANGAS, RIIKKA SALONEN, ULLA PUISTOLA, PEETER KARIHTALA
Anticancer Research Feb 2019, 39 (2) 585-590; DOI: 10.21873/anticanres.13151
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Oxidative Stress-regulating Enzymes and Endometrial Cancer Survival in Relation to Metformin Intake in Diabetic Patients
  • Google Scholar

More in this TOC Section

  • Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus
  • Leveraging Genome-wide Association Studies to Identify Pathogenic Variants for Breast Cancer Among Multiple Continents
  • Growth Suppression and Selective Disruption of F-Actin by α-Santalol in Human Melanoma Cells
Show more Experimental Studies

Similar Articles

Keywords

  • NRF2
  • Keap1
  • DJ-1
  • oxidative stress
  • Endometrial cancer
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire